News

APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer

The former CEO Dr. Hans Loibner will continue to support the Company as senior advisor. Press release Presseaussendung  

July 17, 2018
No Comments
APEIRON, the Medical University of Vienna and the Institute of Molecular Biotechnology Sign Licensing Agreement for a New Checkpoint Inhibitor.

APEIRON strengthens its proprietary Cbl-b portfolio with cutting edge immunotherapy technology developed at IMBA. Presseaussendung Press Release

July 2, 2018
No Comments
EIB Blog featuring APEIRON („Three Ways to Treat Cancer”)

The European Investment Bank blog is featuring APEIRON Biologics AG in following article: http://www.eib.org/stories/new-cancer-treatments

June 25, 2018
No Comments
APEIRON Biologics AG to present clinical data at the forthcoming annual meeting of the American Society of Clinical Oncology (ASCO).

APEIRON Biologics AG today announced it would present data on two of its key programs in three poster presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held on June 1-5, 2018, in Chicago, IL. Presseaussendung Press Release

May 30, 2018
No Comments
APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance With Sanofi

APEIRON Biologics AG and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. Press release Presseaussendung

January 8, 2018
No Comments
APEIRON to Present at the Biotech Showcase™ Annual Conference 2018

APEIRON Biologics AG today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square during one of the most important weeks in healthcare investing. Press release Presseaussendung

January 5, 2018
No Comments
Apeiron Announces Publication of Clinical Data with Anti-GD2 Antibody Demonstrating Efficacy in Relapsed & Refractory High-Risk Neuroblastoma

APEIRON Biologics AG today announced the publication of a successful clinical study in high-risk neuroblastoma patients in the December issue of mAbs, a prominent journal in the monoclonal antibody field. Press release Presseaussendung

December 18, 2017
No Comments
APEIRON Strengthens Management Board with Industry Expert Peter Llewellyn-Davies as New Chief Financial Officer

APEIRON Biologics AG appointed Peter Llewellyn-Davies as new Chief Financial Officer and Chief Business Officer. The biotech and financial expert Llewellyn-Davies is considered an internationally experienced and recognized transaction specialist. After marketing approval of APEIRON’s immunotherapeutic against neuroblastoma the appointment of this strategically important role should prepare the company for its next phase of growth….

October 13, 2017
No Comments